Results 141 to 150 of about 12,515 (211)

The association between FOXO3a rs4946936 gene polymorphism and the levels of FOXO3a among chronic granulocytic leukemia patients treated with imatinib mesylate. [PDF]

F1000Res, 2021
Wardhani SO, Susianti H, Rahayu P, Yueniwati YP, Fajar JK.   +4 more
europepmc   +1 more source

Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase. [PDF]

J Cancer Res Clin Oncol
Zhang J, Zhou S, Jiang S, He F, Tu Y, Hu H.   +5 more
europepmc   +1 more source

Complete laparoscopic wedge resection of a giant locally advanced gastric GIST with near pathological complete response after preoperative treatment with imatinib mesylate: A case report. [PDF]

Int J Surg Case Rep, 2022
Guo H, Li Y, Wang D, Tan B, Yang P, Zhao Q.   +5 more
europepmc   +1 more source

Pharmacokinetic Resistance to Imatinib Mesylate: Role of the ABC Drug Pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the Oral Bioavailability of Imatinib [PDF]

, 2004
Kk Burger, Kees Nooter
openalex   +1 more source

Malignant rectal GIST managed with chemotherapy (Imatinib Mesylate): A case report and a comprehensive review. [PDF]

Radiol Case Rep
Bhusal A, Kc S, Yogi TN, Gupta RK, Kumar A, Khanal B, Katwal S, Neupane D, Lamichhane S, Bhagat R.   +9 more
europepmc   +1 more source

Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model. [PDF]

In Vivo, 2021
Pinto CA, DE Sousa Portilho AJ, Barbosa MC, DE Moraes MEA, DE Lemos JAR, Burbano RMR, Moreira-Nunes CA.   +6 more
europepmc   +1 more source

Imatinib mesylate effectively combines with chaperone‐rich cell lysate‐loaded dendritic cells to treat bcr‐abl⁺ murine leukemia [PDF]

, 2004
Yi Zeng, Michael W. Graner, Hanping Feng, Gang Li, Emmanuel Katsanis   +4 more
openalex   +1 more source

MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate. [PDF]

Int J Mol Sci, 2021
Martins JRB, Moraes LN, Cury SS, Capannacci J, Carvalho RF, Nogueira CR, Hokama NK, Hokama POM.   +7 more
europepmc   +1 more source

Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation [PDF]

, 2004
Paolo Anderlini, Sheetal Sheth, Krystal Hicks, Cindy Ippoliti, Sergio Giralt, Richard E. Champlin   +5 more
openalex   +1 more source

Use of a pH-responsive imatinib mesylate sustained-release hydrogel for the treatment of tendon adhesion by inhibiting PDGFRβ/CLDN1 pathway. [PDF]

Bioact Mater
Pang S, Wu R, Lv W, Zou J, Li Y, Li Y, Zhang P, Ma X, Wang Y, Liu S.   +9 more
europepmc   +1 more source